Pulsed field versus radiofrequency approaches to change vagal nerve effects during pulmonary vein isolation for paroxysmal AF
Official title: A Prospective Randomized Study for the Evaluation of the Impact of Point-by-Point Pulse Field Ablation on Autonomic Nervous System Modulation in Paroxysmal Atrial Fibrillation
Run by VZW Cardiovascular Research Center Aalst · NCT06647485 · Data updated 2026-11-12
This study tests whether pulsed field ablation, alone or combined with radiofrequency, changes vagal nerve activity during pulmonary vein isolation in people with paroxysmal atrial fibrillation.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 105 (estimated) |
| Sponsor | VZW Cardiovascular Research Center Aalst Academic / other |
| Locations | 1 site (Aalst, Belgium) |
| Status | Recruiting |
| Started | January 29, 2025 |
| Main results expected | June 2026 |
| Study ends | December 2026 |
| Registry record updated | July 10, 2025 |
| Trial ID | NCT06647485 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18–70 with symptomatic paroxysmal atrial fibrillation that terminates within seven days, who are eligible for point-by-point pulmonary vein isolation and can complete follow-up testing.
✕Probably not a fit
Patients with persistent AF, prior left atrial ablation or cardiac surgery, severe left ventricular dysfunction, intracardiac thrombus, or implanted pacemakers/ICDs (and other listed exclusions) would not be eligible and are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized interventional study compares three point-by-point pulmonary vein isolation approaches: pulsed field (PF) only, a hybrid PF posterior/RF anterior approach, and RF-only as the control. Heart rate variability (HRV) will be used as a surrogate marker of ganglionated plexi and measured before and 24 hours after the procedure, while troponin and S100B biomarkers are sampled before and 20 minutes after ablation. Participants are followed for 12 months with 24-hour Holter ECGs at 3, 6, and 12 months to monitor rhythm outcomes and longer-term autonomic effects. The trial enrolls adults with symptomatic paroxysmal AF suitable for catheter ablation and excludes those with prior left atrial ablation, recent MI, severe LV dysfunction, intracardiac thrombus or implanted cardiac metal devices.
Why it matters
Potential benefit: If successful, the approach could guide ablation strategies that reduce unwanted autonomic effects and improve symptom control for people with paroxysmal AF.
How similar studies have gone: Pulsed field ablation has shown promising safety and efficacy for pulmonary vein isolation in recent studies, but its specific effects on autonomic ganglia and combinations with RF energy are not well established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Symptomatic Paroxysmal Atrial Fibrillation (AF) that terminates spontaneously or with intervention within 7 days of onset * Age range: 18-70 years * Willing and capable of providing informed consent * Able and willing to comply with all pre-, post-, and follow-up testing and requirements Exclusion Criteria: * Previously diagnosed Persistent AF (\> 7 days in duration) * Previous LA ablation * Previous cardiac surgery * Myocardial Infarction within the previous 3 months * Severely compromised Left Ventricular Ejection Fraction (LVEF\<40%) * Presence of implanted pacemaker or Implantable Cardioverter-Defibrillator (ICD) or other implanted metal cardiac device that may interfere with the pulsed electric field energy * Acute illness, active systemic infection, or sepsis * Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation. * Severe mitral regurgitation * Woman who are pregnant, lactating, or who are planning to become pregnant during the course of the clinical investigation
Where it's running
-
OLV Hospital
Aalst, Belgium, Belgium Recruiting
Study contacts
- Principal investigator: Tom De Potter, MD — Cardiovascular Research Center Aalst
- Study coordinator: Chiara Valeriano, MD
- Email: chiara.valeriano91@gmail.com
- Phone: +34 697539354
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Budiodarone for paroxysmal AF: a dose-escalation safety and feasibility study
This study tests whether budiodarone is safe and helps control paroxysmal atrial fibrillation in about 100 adults over 6 months, using dose adjustments guided by AF monitoring.
-
Left Atrial Appendage Occlusion and Rhythm Restoration in AF Patients
This trial tests a combined procedure using the Volt PFA System and Amulet 2 to see if it safely and feasibly treats atrial fibrillation while also closing the left atrial appendage in adults with AF.
-
Coherent Sine-Burst Electroporation (CSE) Ablation for Atrial Fibrillation
This study will test whether the Argá Medtech CSE electroporation device can safely and effectively ablate heart tissue to treat adults with symptomatic paroxysmal or persistent atrial fibrillation who have not responded to drugs.
-
Pulsed Field vs Cryoballoon for Pulmonary Vein Isolation in Atrial Fibrillation
This trial tests whether pulsed field ablation can shorten the procedure for first-time PVI in AF patients compared with cryoballoon ablation, while keeping safety and effectiveness similar.
-
Pulsed Field Ablation vs Cryoablation for Atrial Fibrillation Under Deep Sedation
This trial tests whether pulsed field ablation (PFA) done under deep sedation works as well as cryoballoon ablation for treating atrial fibrillation, aiming to avoid general anesthesia.
-
Bachmann’s Bundle Pacing vs Right Atrial Appendage Pacing for AF
This study tests two common atrial pacing methods to see which one is safer over 12 months for people getting a new pacemaker, ICD, or CRT device.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.